Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07250750 · ClinicalTrials.gov registry record · Phase 1

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

A Phase 1 study of Myasthenia Gravis, sponsored by ImmunAbs.

Recruiting
Registry status
Phase 1
Development phase
96
Enrollment target
20
Study locations

NCT07250750 is a Phase 1 study of Myasthenia Gravis that is actively recruiting participants, run by ImmunAbs. The registered enrollment target is 96 participants, below the 188-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07250750, a Phase 1 study of Myasthenia Gravis, is actively recruiting participants, sponsored by ImmunAbs.

RECRUITING
Registry status
Phase 1
Development phase
96 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in participants with AChR antibody-negative gMG and participants with AChR antibody-positive or AChR antibody-negative oMG.

Conditions Studied

Interventions

  • DRUG IM-101 Part A
  • DRUG Placebo Part A
  • DRUG IM-101 Part B
  • DRUG Placebo Part B

Study Locations (20)

Other

  • Medical Center Hera - branch Montana - Montana
  • "MHAT Avis - Medica" OOD - Pleven
  • UMHAT 'Dr. Georgi Stranski', EAD - Pleven
  • UMHAT 'Tsaritsa Yoanna - ISUL', EAD - Sofia
  • Haelan Care 4 Medical Center EOOD - Varna
  • Neurologia Slaska Centrum Medyczne - Katowice
  • Twoja Przychodnia NCM - Nowa Sól
  • Twoja Przychodnia PCM - Poznan
  • NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy - Poznan

Florida

  • Neurology of Central Florida Research Center, LLC - Altamonte Springs
  • SFM Clinical Research, LLC - Boca Raton
  • Aqualane Clinical Research - Naples
  • Medsol Clinical Research Center - Port Charlotte
  • University of South Florida - Tampa

Texas

  • Nerve & Muscle Center of Texas - Houston
  • Houston Methodist Neurological Institute - Houston

Milano

  • Ospedale San Raffaele - Milan
  • Fondazione IRCCS Istituto Neurologico Carlo Besta - Milan

Missouri

  • University of Kansas Medical Center Research Institute, Inc. - Kansas City

Brescia

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili) - Brescia

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2026-02-05
Est. Completion 2028-06
Phase Phase 1

Sponsor

ImmunAbs

1 total trials

What the Registry Record Tells You About NCT07250750

The ClinicalTrials.gov registry entry for NCT07250750 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (49% lower). The listed sponsor is ImmunAbs, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 4 interventions - of which IM-101 Part A is the first listed.

NCT07250750 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07250750 about?

NCT07250750 is a clinical study titled "A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis". The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in par...

What is the current status of trial NCT07250750?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2026-02-05. Estimated completion is 2028-06.

What conditions does trial NCT07250750 study?

This clinical trial studies the following conditions: Myasthenia Gravis.

What interventions are being tested in trial NCT07250750?

The interventions under investigation include: IM-101 Part A (DRUG), Placebo Part A (DRUG), IM-101 Part B (DRUG), Placebo Part B (DRUG).

Who is sponsoring clinical trial NCT07250750?

This trial is sponsored by ImmunAbs, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07250750 being conducted?

This trial has 20 study locations across Florida, Missouri, Texas, Brescia, Milano. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.